EPISODE · Jun 16, 2022 · 16 MIN
Bonus: What You Need to Know About the Novavax COVID-19 Protein-Based Vaccine
from Public Health On Call · host The Johns Hopkins Bloomberg School of Public Health
An FDA advisory panel recommended Emergency Use Authorization for the two-dose Novavax COVID-19 vaccine for people ages 18+. The vaccine is built on a different technology than others currently authorized in the US, and significant delays in manufacturing and authorization have slowed down its entry into the US market. Vaccine expert Dr. Bill Moss returns to the podcast to talk with Lindsay Smith Rogers about Novavax and its potential and what's behind the delays.
NOW PLAYING
Bonus: What You Need to Know About the Novavax COVID-19 Protein-Based Vaccine
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m